Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy
AbstractIgA nephropathy is a common disease that causes end-stage renal failure and requires renal replacement therapy. The main purpose of therapeutic intervention in this disease is not limited to improvement of prognosis and prevention of transition to end-stage renal failure, but also prevention of the occurrence of cardiovascular lesions, which increases risk in patients with chronic kidney disease. Steroids and immunosuppressants have been widely used as remission induction therapies; however, the balance between their therapeutic benefits and detrimental side-effects are controversial. In this regard, it is critical to identify alternative therapies which would provide holistic life-long benefits. Currently, the potential of ω-3 fatty acids as anti-inflammatory and inflammation-convergent drugs—especially the remarkable progress of the multifunctional ω-3 polyunsaturated fatty acids (PUFAs)—has garnered attention. In this section, we outline the background and current status of ω-3 PUFA-based treatment in IgA nephropathy. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Hirahashi, J. Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy. J. Clin. Med. 2017, 6, 70.
Hirahashi J. Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy. Journal of Clinical Medicine. 2017; 6(7):70.Chicago/Turabian Style
Hirahashi, Junichi. 2017. "Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy." J. Clin. Med. 6, no. 7: 70.